Profound CD8+ T cell immunity elicited by sequential daily immunization with exogenous antigen plus the TLR3 agonist poly(I:C)

Vaccine

Volumn 29, Issue 5, 2011, Pages 984-993

  Wick, Darin A ^a   Martin, Spencer D ^a,b   Nelson, Brad H ^a,b   Webb, John R ^a,b  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF VICTORIA   (Canada)

Author keywords

CD8+ T cells; TLR3; Vaccine

Indexed keywords

OVALBUMIN; POLYINOSINIC POLYCYTIDYLIC ACID; PROTEIN E7;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOTOXICITY; DRUG EFFECT; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; IMMUNIZATION; INJECTIONS, SUBCUTANEOUS; MICE; MICE, INBRED C57BL; OVALBUMIN; PAPILLOMAVIRUS E7 PROTEINS; POLY I-C; TOLL-LIKE RECEPTOR 3;

EID: 78751585019     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.11.036     Document Type: Article

References (34)

1. Carbone F.R., Bevan M.J. Class I-restricted processing and presentation of exogenous cell-associated antigen in vivo. J Exp Med 1990, 171(2):377-387.
2. Zinkernagel R.M., Hengartner H. Protective 'immunity' by pre-existent neutralizing antibody titers and preactivated T cells but not by so-called 'immunological memory'. Immunol Rev 2006, 211:310-319.
3. Pantaleo G., Koup R.A. Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nat Med 2004, 10(8):806-810.
4. Appay V., Douek D.C., Price D.A. CD8+ T cell efficacy in vaccination and disease. Nat Med 2008, 14(6):623-628.
5. Berzofsky J.A., Ahlers J.D., Belyakov I.M. Strategies for designing and optimizing new generation vaccines. Nat Rev Immunol 2001, 1(3):209-219.
6. Plotkin S.A. Vaccines: past, present and future. Nat Med 2005, 11(4 Suppl.):S5-11.
7. Murali-Krishna K., Altman J.D., Suresh M., Sourdive D.J., Zajac A.J., Miller J.D., et al. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity 1998, 8(2):177-187.
8. Draper S.J., Heeney J.L. Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol 2010, 8(1):62-73.
9. Buchbinder S.P., Mehrotra D.V., Duerr A., Fitzgerald D.W., Mogg R., Li D., et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008, 372(9653):1881-1893.
10. Lu S. Heterologous prime-boost vaccination. Curr Opin Immunol 2009, 21(3):346-351.
11. Radosevic K., Rodriguez A., Lemckert A., Goudsmit J. Heterologous prime-boost vaccinations for poverty-related diseases: advantages and future prospects. Expert Rev Vaccines 2009, 8(5):577-592.
12. Ranasinghe C., Ramshaw I.A. Genetic heterologous prime-boost vaccination strategies for improved systemic and mucosal immunity. Expert Rev Vaccines 2009, 8(9):1171-1181.
13. Kantoff P.W., Higano C.S., Shore N.D., Berger E.R., Small E.J., Penson D.F., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363(5):411-422.
14. Bijker M.S., Melief C.J., Offringa R., van der Burg S.H. Design and development of synthetic peptide vaccines: past, present and future. Expert Rev Vaccines 2007, 6(4):591-603.
15. Datta S.K., Redecke V., Prilliman K.R., Takabayashi K., Corr M., Tallant T., et al. A subset of Toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells. J Immunol 2003, 170(8):4102-4110.
16. Salio M., Cerundolo V. Viral immunity: cross-priming with the help of TLR3. Curr Biol: CB 2005, 15(9):R336-R339.
17. Schulz O., Diebold S.S., Chen M., Naslund T.I., Nolte M.A., Alexopoulou L., et al. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 2005, 433(7028):887-892.
18. Shaulov A., Murali-Krishna K. CD8 T cell expansion and memory differentiation are facilitated by simultaneous and sustained exposure to antigenic and inflammatory milieu. J Immunol 2008, 180(2):1131-1138.
19. Zaks K., Jordan M., Guth A., Sellins K., Kedl R., Izzo A., et al. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J Immunol (Baltimore, MD: 1950) 2006, 176(12):7335-7345.
20. Goldberger O., Volovitz I., Machlenkin A., Vadai E., Tzehoval E., Eisenbach L. Exuberated numbers of tumor-specific T cells result in tumor escape. Cancer Res 2008, 68(9):3450-3457.
21. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., Schreiber R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002, 3(11):991-998.
22. Wang Y., Cella M., Gilfillan S., Colonna M. Cutting edge: polyinosinic:polycytidylic acid boosts the generation of memory CD8 T cells through melanoma differentiation-associated protein 5 expressed in stromal cells. J Immunol 2010, 184(6):2751-2755.
23. Fujimoto C., Nakagawa Y., Ohara K., Takahashi H. Polyriboinosinic polyribocytidylic acid [poly(I:C)]/TLR3 signaling allows class I processing of exogenous protein and induction of HIV-specific CD8+ cytotoxic T lymphocytes. Int Immunol 2004, 16(1):55-63.
24. Kemeny N., Yagoda A., Wang Y., Field K., Wrobleski H., Whitmore W. Randomized trial of standard therapy with or without poly I:C in patients with superficial bladder cancer. Cancer 1981, 48(10):2154-2157.
25. Krown S.E., Kerr D., Stewart W.E., Field A.K., Oettgen H.F. Phase I trials of poly(I,C) complexes in advanced cancer. J Biol Response Mod 1985, 4(6):640-649.
26. Cheever M.A. Twelve immunotherapy drugs that could cure cancers. Immunol Rev 2008, 222:357-368.
27. Miller J.D., van der Most R.G., Akondy R.S., Glidewell J.T., Albott S., Masopust D., et al. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 2008, 28(5):710-722.
28. Woodland D.L. Jump-starting the immune system: prime-boosting comes of age. Trends Immunol 2004, 25(2):98-104.
29. Jiang G., Shi M., Conteh S., Richie N., Banania G., Geneshan H., et al. Sterile protection against Plasmodium knowlesi in rhesus monkeys from a malaria vaccine: comparison of heterologous prime boost strategies. PLoS One 2009, 4(8):e6559.
30. Belz G.T., Zhang L., Lay M.D., Kupresanin F., Davenport M.P. Killer T cells regulate antigen presentation for early expansion of memory, but not naive, CD8+ T cell. Proc Natl Acad Sci U S A 2007, 104(15):6341-6346.
31. Melief C.J., van der Burg S.H. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer 2008, 8(5):351-360.
32. Tindle R.W., Fernando G.J., Sterling J.C., Frazer I.H. A "public" T-helper epitope of the E7 transforming protein of human papillomavirus 16 provides cognate help for several E7 B-cell epitopes from cervical cancer-associated human papillomavirus genotypes. Proc Natl Acad Sci U S A 1991, 88(13):5887-5891.
33. van der Burg S.H. Therapeutic vaccines in cancer: moving from immunomonitoring to immunoguiding. Expert Rev Vaccines 2008, 7(1):1-5.
34. Kochenderfer J.N., Gress R.E. A comparison and critical analysis of preclinical anticancer vaccination strategies. Exp Biol Med (Maywood) 2007, 232(9):1130-1141.